Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Jialei Qi, Sascha Endres, Deyan Yordanov Yosifov, Eugen Tausch, Rashmi Priyadharshini Dheenadayalan, Xiang Gao, Annika Scheffold, Felix Seyfried, Lüder Meyer, Christof Schneider, Daniel Mertens, Peter Gierschik, Martin Wist, Stephan Stilgenbauer, Billy Michael Chelliah Jebaraj

Blood (2022) 140 (Supplement 1): 3139–3141.

https://doi.org/10.1182/blood-2022-159427

Published: 2022

Journal Articles

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, André Lechel, Sarah-Fee Katz, PhD, Eugen Tausch, Johannes Bloehdorn, MD, Daniela Steinbrecher, PhD, Vanni Torresi, Christof Schneider, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Lenhard Rudolph, Stephan Stilgenbauer

Blood (2019) 134 (Supplement_1): 1732.

https://doi.org/10.1182/blood-2019-126878

Published: 2019

Journal Articles

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Blood (2019) 134 (6): 534–547.

https://doi.org/10.1182/blood.2018881029

Published: 2019

Includes: Supplemental data

Journal Articles

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, Eugen Tausch, MD, Judith A. Fox, PhD, Pietro Taverna, PhD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2018-99-116664

Published: 2018

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

Generation of a Lenalidomide-Sensitive Mouse Model for Multiple Myeloma By Expression of the Crbn I391V Mutant in Mopc-315.BM Cells

Dilan Serdar, Simon Köpff, Annika Scheffold, Jan Kronke

Blood (2017) 130 (Supplement 1): 3071.

https://doi.org/10.1182/blood.V130.Suppl_1.3071.3071

Published: 2017

Journal Articles

PI3K-δ Inhibition Influences T-Cell Populations and Anti-Tumoral Immune Function in Preclinical Models

Annika Scheffold, Bola S Hanna, PhD, Philipp Roeßner, Yasmin Demerdash, Billy Michael Chelliah Jebaraj, PhD, Peter Lichter, PhD, Stephan Stilgenbauer, MD PhD, Martina Seiffert

Blood (2017) 130 (Supplement 1): 2998.

https://doi.org/10.1182/blood.V130.Suppl_1.2998.2998

Published: 2017

Journal Articles

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Eugen Tausch, MD, Sven Estenfelder, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 1708.

https://doi.org/10.1182/blood.V130.Suppl_1.1708.1708

Published: 2017

Journal Articles

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Paolo Ghia, Viktor Ljungström, Eugen Tausch, Andreas Agathangelidis, Annika Scheffold, Lydia Scarfo, Billy Michael Chelliah Jebaraj, Carolyn J. Owen, MD MDes(UK), FRCPC, Jacqueline C. Barrientos, MD, Marc Zapatka, Veerendra Munugalavadla, Jeremiah D. Degenhardt, Yeonhee Kim, Ronald L. Dubowy, Lyndah K. Dreiling, Richard Rosenquist, Stephan Stilgenbauer

Blood (2016) 128 (22): 2770.

https://doi.org/10.1182/blood.V128.22.2770.2770

Published: 2016

Journal Articles

Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

Felix Seyfried, MD, Salih Demir, MSc, Rebecca Hörl, Stefan Köhrer, Annika Scheffold, Stephan Stilgenbauer, Klaus-Michael Debatin, MD PhD, Lüder Hinrich Meyer, MD

Blood (2016) 128 (22): 1081.

https://doi.org/10.1182/blood.V128.22.1081.1081

Published: 2016

Journal Articles

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Anella Yahiaoui, Anna Dolnik, PhD, Tamara Jacqueline Blaette, M.sc., Lars Bullinger, MD, Christof Schneider, MD, Daniel Mertens, PhD, Veerendra Munugalavadla, Shih-Shih Chen, PhD, Nicholas Chiorazzi, MD, Stacey Tannheimer, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2016) 128 (22): 190.

https://doi.org/10.1182/blood.V128.22.190.190

Published: 2016

Journal Articles

Microenvironmental Stromal Cells Rescue CLL Cells from Apoptosis Via Hypoxia That Can be Targeted Therapeutically

Irina Idler, PhD, Deyan Yosifov, PhD, Nupur Bhattacharya, PhD, Michaela Reichenzeller, PhD, Viola Meyer-Pannwitt, Daria Ezerina, Annika Scheffold, M.Sc., Sabrina Kugler, PhD, Tobias Dick, PhD, Hartmut Dohner, MD, Stephan Stilgenbauer, MD, Daniel Mertens, PhD

Blood (2015) 126 (23): 4140.

https://doi.org/10.1182/blood.V126.23.4140.4140

Published: 2015

Journal Articles

Eµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

Annika Scheffold, M.Sc., Billy Michael Chelliah Jebaraj, PhD, André Lechel, PhD, Sarah-Fee Katz, PhD, Daniela Steinbrecher, M.Sc., Vanni Torresi, M.Sc., Christof Schneider, MD, Daniel Mertens, PhD, Hartmut Döhner, MD, Karl-Lenhard Rudolph, MD, Stephan Stilgenbauer, MD

Blood (2015) 126 (23): 1724.

https://doi.org/10.1182/blood.V126.23.1724.1724

Published: 2015

Journal Articles

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Annika Scheffold, MSc, Billy Michael Chelliah Jebaraj, PhD, Eugen Tausch, MD, Sebastian Boettcher, MD, Matthias Ritgen, Donald Bunjes, MD, Matthias Zeis, MD, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MDPhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD PhD, Norbert Schmitz, MD PhD, Hartmut Doehner, MD, Peter Dreger, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1951.

https://doi.org/10.1182/blood.V124.21.1951.1951

Published: 2014

NARROW

Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Generation of a Lenalidomide-Sensitive Mouse Model for Multiple Myeloma By Expression of the Crbn I391V Mutant in Mopc-315.BM Cells

PI3K-δ Inhibition Influences T-Cell Populations and Anti-Tumoral Immune Function in Preclinical Models

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Microenvironmental Stromal Cells Rescue CLL Cells from Apoptosis Via Hypoxia That Can be Targeted Therapeutically

Eµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only